Can a quantitative serum levetiracetam (Keppra) level be obtained to assess toxicity, and how long does it take to receive the results?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Levetiracetam (Keppra) Serum Level Testing and Toxicity Assessment

Yes, quantitative serum levetiracetam levels can be obtained to assess toxicity, but routine therapeutic drug monitoring is NOT necessary for levetiracetam management. 1 The turnaround time for results typically ranges from several hours to 1-2 days depending on your laboratory's capabilities, as most facilities send these tests to reference laboratories rather than performing them in-house.

Clinical Context for Levetiracetam Monitoring

Levetiracetam does not require routine therapeutic drug monitoring because it has:

  • Linear, predictable pharmacokinetics 1
  • Minimal protein binding (<10%) 1
  • No significant drug-drug interactions via cytochrome P450 enzymes 1
  • Low intra- and inter-subject variability 1

The therapeutic range is generally cited as 12-46 μg/mL (or 10-37 μg/mL in some references) 2, 3, though clinical response does not always correlate tightly with serum levels.

When to Consider Checking Levels

Specific Clinical Scenarios:

  • Suspected toxicity/overdose: Somnolence, agitation, aggression, depressed consciousness, or respiratory depression 1
  • Refractory seizures despite adequate dosing: To verify therapeutic levels are achieved 2, 4
  • Compliance concerns: Unexpectedly low or absent seizure control 2
  • Renal impairment: Levetiracetam is 66% renally excreted unchanged; dose adjustment needed when CrCl is reduced 1
  • Co-administration with enzyme-inducing antiepileptics: Phenytoin, carbamazepine, and oxcarbazepine can decrease levetiracetam levels by 20-30% 5
  • Critical illness: ICU patients eliminate levetiracetam more rapidly and may need higher doses 4

Laboratory Testing Details

Available Assays:

Multiple validated methods exist for measuring levetiracetam:

  • LC-MS/MS (liquid chromatography-tandem mass spectrometry): Most accurate, within-day CV <6.1%, between-day CV <8.2% 6
  • HPLC with photodiode array detection: Reliable alternative method 2
  • Capillary electrophoresis: Simpler, rapid method 7

Turnaround Time:

  • In-house testing: 2-6 hours if your facility has the capability (uncommon)
  • Send-out testing: 24-48 hours (most common scenario)
  • STAT requests: May be available at some reference labs within 4-8 hours

Critical point: The delay in obtaining results means levels are primarily useful for confirming suspected toxicity retrospectively or adjusting chronic therapy, NOT for acute management decisions.

Toxicity Assessment and Management

Clinical Features of Levetiracetam Toxicity:

The overdose case report 3 with a level of 400 μg/mL (10-40 times therapeutic) demonstrated:

  • Obtundation and respiratory depression requiring intubation
  • Diminished deep tendon reflexes
  • Rapid recovery with supportive care (extubated next day)
  • Elimination half-life remained normal at 5.14 hours even at toxic levels

Management Algorithm:

  1. Assess clinical status: Focus on level of consciousness, respiratory drive, and neurological exam
  2. Provide supportive care: Airway protection if needed, monitor vital signs 1
  3. Consider gastric decontamination: Only if recent ingestion (<1 hour) and patient can protect airway 1
  4. Hemodialysis for severe cases: Removes approximately 50% of levetiracetam in 4 hours 1
    • Consider if: severe CNS depression, respiratory failure, or significant renal impairment
  5. Send serum level: For confirmation and prognostication, but do NOT wait for results to initiate treatment

Key Toxicity Considerations:

  • No specific antidote exists 1
  • Most overdoses resolve with supportive care alone 1, 3
  • Adverse effects in therapeutic use include somnolence, agitation, behavioral problems, and rarely psychosis 8, 9, 10
  • Psychiatric side effects are a concern even at therapeutic doses 11

Practical Recommendations

For acute suspected toxicity:

  • Treat clinically based on symptoms
  • Send level for confirmation but proceed with supportive care immediately
  • Contact Poison Control Center for guidance 1

For chronic therapy optimization:

  • Check trough levels (just before next dose) at steady state (after 2 days of dosing) 1
  • Target 12-46 μg/mL, but prioritize clinical seizure control over arbitrary numbers 2
  • In critically ill patients, consider higher maintenance doses (750-1000 mg BID vs 500 mg BID) as underdosing is common 4

Common pitfall: Ordering levels routinely without clinical indication wastes resources and delays results, as levetiracetam does not require monitoring like phenytoin or valproate.

References

Research

A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.

Journal of toxicology. Clinical toxicology, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.